Study of CTS-1027 in Hepatitis C Patients

This study has been completed.
Sponsor:
Collaborator:
FGK Clinical Research GmbH
Information provided by:
Conatus Pharmaceuticals Inc.
ClinicalTrials.gov Identifier:
NCT00570336
First received: December 6, 2007
Last updated: September 14, 2010
Last verified: September 2010

December 6, 2007
September 14, 2010
December 2007
July 2009   (final data collection date for primary outcome measure)
  • Number of adverse events at each dose level [ Time Frame: 4 to 24 weeks ] [ Designated as safety issue: Yes ]
  • Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) levels at each dose [ Time Frame: 4-24 Weeks ] [ Designated as safety issue: Yes ]
Safety of CTS-1027 demonstrated by adverse events, vital signs, labs, and ECG. Efficacy demonstrated by reduction in aminotransferases [ Time Frame: 4 to 12 weeks ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00570336 on ClinicalTrials.gov Archive Site
Peak and trough levels of CTS-1027 in plasma [ Time Frame: 4 to 24 weeks ] [ Designated as safety issue: Yes ]
Assess the peak and trough levels of CTS-1027 in plasma [ Time Frame: 4 to 12 weeks ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Study of CTS-1027 in Hepatitis C Patients
A Dose Response Study of CTS-1027 in Hepatitis C Patients

The purpose of this study is to determine if CTS-1027 can lower elevated liver enzymes in patients with chronic HCV infection.

Randomized, placebo-controlled, double-blind, parallel group, multicenter, dose response trial utilizing four doses of CTS-1027, administered orally once daily, in outpatients with chronic hepatitis C virus (HCV) infection.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Chronic Hepatitis C Virus Infection
  • Drug: CTS-1027
    Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd (quaque die, once daily).
  • Other: Placebo
    Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd.
  • Experimental: 2.5 milligram (mg) CTS-1027
    2.5 mg CTS-1027
    Intervention: Drug: CTS-1027
  • Experimental: 5 mg CTS-1027
    5 mg CTS-1027
    Intervention: Drug: CTS-1027
  • Experimental: 10 mg CTS-1027
    10 mg CTS-1027
    Intervention: Drug: CTS-1027
  • Experimental: 30 mg CTS-1027
    30 mg CTS-1027
    Intervention: Drug: CTS-1027
  • Placebo Comparator: Placebo
    Placebo
    Intervention: Other: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
87
July 2009
July 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female patients of minimum adult legal age (according to local laws for signing the informed consent document), able to provide written informed consent, and understand and comply with the requirements of the trial
  • A history of chronic HCV infection
  • Unsuccessful HCV treatment defined as one or more of the following criteria:

    1. Failure to achieve a virologic response during previous therapy, or
    2. Failure to tolerate therapy, or
    3. Failure to maintain a sustained virologic response, or
    4. In the opinion of the Principal Investigator, the patient is not a suitable candidate for interferon based therapy
  • Liver impairment, as defined by either aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) levels 1.5 - 7 x ULN on at least two occasions, seven or more days apart, during the baseline period
  • Alpha-fetoprotein (AFP) <= 50 ng/mL
  • Hemoglobin >= 10 g/dL, platelet count >= 75 x 109/L, and white blood cell count >= 1.5 x 109/L
  • Willingness to utilize adequate contraception (if female, evidenced by being postmenopausal for at least 6 months or using contraceptive pill; for both females and males, being surgically sterile, or using two forms of barrier contraception) from screening to at least one month after the completion of the trial.

Exclusion Criteria:

  • Decompensated or severe liver disease defined by one or more of the following criteria:

    1. Prior liver biopsy showing cirrhosis
    2. Prior liver biopsy showing bridging fibrosis (Metavir >2 or Ishak >3) more than 2 years ago in the absence of newer liver biopsy results
    3. Prothrombin time: 3 seconds > control
    4. Total bilirubin >= 1.5 x Upper limit of the normal range (ULN), or > 3 x ULN for unconjugated bilirubin
    5. Serum albumin below normal limits
    6. AST or ALT > 7 x ULN during baseline period
    7. Evidence of portal hypertension including:
  • Splenomegaly or evidence of portal hypertension (i.e., enlarged portal vein and varices) on ultrasound,
  • Varices in esophagogastroduodenoscopy (EGD); or
  • Ascites
  • Hepatocellular carcinoma (HCC) or suspicion of HCC clinically or on ultrasound (or other imaging techniques)
  • Known history or presence of human immunodeficiency virus (HIV) infection
  • Co-infection with hepatitis B virus (HBV)
  • If female: pregnant, lactating, or positive serum or urine pregnancy test
  • Last baseline AST and ALT level prior to Day 1 of < 1.5 x ULN
  • Renal impairment (creatinine > 1.5 x ULN) or hepatorenal syndrome
  • Pancreatitis
  • Hospitalization for liver disease within 60 days of screening
  • Use of concomitant or prior drug therapy for HCV at screening, including the use of:

    1. drugs with presumed anti-HCV activity in the prior three months
    2. corticosteroids in the past 30 days
    3. potentially hepatotoxic drugs in the past 30 days (including alpha methyl-dopa, sodium valproic acid, isoniazide, or nitrofurantoin)
  • Use of illicit or drugs of abuse in the prior three months (allowed if medically prescribed or indicated)
  • History of alcohol abuse within the past year
  • History or presence of clinically concerning cardiac arrhythmias or prolongation of pre-dose QT or QTc interval of > 450 milliseconds
  • Other concomitant disease or condition likely to significantly decrease life expectancy (e.g., moderate to severe congestive heart failure) or any malignancy other than curatively treated skin cancer (basal cell or squamous cell carcinomas), unless adequately treated or in complete remission for ten or more years
  • Any patient who has received any investigational drug or device within 30 days of dosing, or who is scheduled to receive another investigational drug or device during the course of this trial.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00570336
CTS-1027-01
Yes
MiRa Huyghe, Conatus Pharmaceuticals Inc.
Conatus Pharmaceuticals Inc.
FGK Clinical Research GmbH
Study Director: William Frank, MD Conatus Pharmaceuticals Inc.
Conatus Pharmaceuticals Inc.
September 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP